TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05972577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Undergo GO!

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear accelerometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessments and diary entries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05835167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior part-sternotomy
Description: A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full median sternotomy
Description: A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
Study: NCT06484179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Self-Help
Description: In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive the standard care typically offered for smoking cessation.
Study: NCT04764097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: SGTL2 Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05132179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution
Description: Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
Study: NCT03986502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch web-based financial literacy video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information on financial counseling and medical cost assistance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Utilize usual clinic procedures and clinic or community-based financial resources

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05206214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual glide path
Description: manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical glide path
Description: glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
Study: NCT06167863

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: extracted image features from CT or MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: extracted image features from CT or MRI
Study: NCT04576923

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Velacur by Sonic Incytes
Description: liver stiffness measurement
Study: NCT05700058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein supplement
Description: 3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
Study: NCT04451681

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiopulmonary exercise test
Description: Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
Study: NCT05274321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanodropper
Description: Device used for administering eye drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Eye Dropper
Description: Standard Eye Dropper used for administering eye drops
Study: NCT05126342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
Study: NCT04856423

Intervention type: DIAGNOSTIC_TEST
Intervention: The us-qFIT and colonoscopy with pathological examination
Description: Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
Study: NCT06007911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level -1
Description: 25 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level -1
Description: 25 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level -1
Description: 25 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level -1
Description: 25 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 0
Description: 50 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 0
Description: 50 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 0
Description: 50 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 0
Description: 50 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 1
Description: 75 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 1
Description: 75 mg by mouth on days 1-10.
Study: NCT05126342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
Study: NCT06007911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 1
Description: 75 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 1
Description: 75 mg by mouth on days 1-10.
Study: NCT05756205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR)
Description: The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator.
Study: NCT06388460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Link
Description: Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Providers enroll patients to receive an asthma educational workbook
Study: NCT05526092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention
Description: Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
Study: NCT05291741

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VLCD
Description: Advice regarding VLCD

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard dietary advice for weight loss before bariatric surgery
Study: NCT05122013

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy
Description: A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
Study: NCT06007911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 2
Description: 100 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 2
Description: 100 mg by mouth on days 1-10.
Study: NCT05368571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHOICES-TEEN
Description: This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health and Life Skills Education
Description: This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
Study: NCT05239923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Description: Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
Study: NCT06302868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Exposure Therapy Using Photos and Videos
Description: Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine-Based Virtual Reality Exposure Therapy
Description: Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
Study: NCT05657080

Intervention type: DEVICE
Intervention: Cytosponge-TFF3
Description: Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
Study: NCT06007911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 2
Description: 100 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax Dose Level 2
Description: 100 mg by mouth on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Level -1
Description: 400 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Level -1
Description: 400 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Level -1
Description: 400 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Level -1
Description: 400 mg by mouth on days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Dose Levels 0 to 2
Description: 400 mg by mouth on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.
Study: NCT04964505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study: NCT06007911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.
Study: NCT04964505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04757480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar Interfascial Plane Block (TLIP)
Description: (20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
Study: NCT04772911

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
Study: NCT04962204

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual meeting between patients/physicians and caregiver
Description: Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
Study: NCT05333978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Device
Description: The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
Study: NCT06342414

Intervention type: DIAGNOSTIC_TEST
Intervention: ELUCIDATE
Description: ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)

Intervention type: DIAGNOSTIC_TEST
Intervention: ELUCIDATE
Description: ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)

Intervention type: DIAGNOSTIC_TEST
Intervention: ELUCIDATE
Description: ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)

Intervention type: DIAGNOSTIC_TEST
Intervention: ELUCIDATE
Description: ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
Study: NCT06301685

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine therapy
Description: The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine therapy
Description: The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT00012805

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone Monitoring
Study: NCT06301685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
Study: NCT05664971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Description: 200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study: NCT04835441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-101
Description: Blinded ALPN-101 will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo matching ALPN-101 will be administered.
Study: NCT04739917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C+R 150 mcg
Description: Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C+R 150 mcg
Description: Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SSN Montanide ISA-51 1 mL
Description: SSN Montanide ISA-51 1 mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SSN Montanide ISA-51 1 mL
Description: SSN Montanide ISA-51 1 mL